Seres Therapeutics Inc(MCRB) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Current Price

$20.73

RSI

43.883

Beta:

3.995587

March 02, 2021
25.1M
-18.2M

130.438 %
47.557 %
3.770 %
-12.100 %

$33,215,000
$34,505,000
$28,267,000
$32,100,000
$21,766,000
$0
-3.884 %
22.068 %
-13.560 %
47.478 %
0.000 %

$-89,127,000
$-70,279,000
$-98,942,000
$-89,380,000
$-91,579,000
$-54,780,000
-21.147 %
40.785 %
-9.664 %
2.460 %
-40.183 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.